EP Patent

EP1255536B1 — Indolinone derivatives for modulation of c-kit tyrosine protein kinase

Assigned to Sugen LLC · Expires 2006-06-28 · 20y expired

What this patent protects

The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.

USPTO Abstract

The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.

Drugs covered by this patent

Patent Metadata

Patent number
EP1255536B1
Jurisdiction
EP
Classification
—
Expires
2006-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Sugen LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.